GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (LTS:0NZT) » Definitions » Short-Term Debt

UCB (LTS:0NZT) Short-Term Debt : €-1 Mil (As of Jun. 2024)


View and export this data going back to 2009. Start your Free Trial

What is UCB Short-Term Debt?

UCB's Short-Term Debt for the quarter that ended in Jun. 2024 was €-1 Mil.

UCB's quarterly Short-Term Debt declined from Jun. 2023 (€227 Mil) to Dec. 2023 (€-1 Mil) but then stayed the same from Dec. 2023 (€-1 Mil) to Jun. 2024 (€-1 Mil).

UCB's annual Short-Term Debt increased from Dec. 2021 (€17 Mil) to Dec. 2022 (€222 Mil) but then declined from Dec. 2022 (€222 Mil) to Dec. 2023 (€-1 Mil).


UCB Short-Term Debt Historical Data

The historical data trend for UCB's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB Short-Term Debt Chart

UCB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 268.00 396.00 17.00 222.00 -1.00

UCB Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 81.00 222.00 227.00 -1.00 -1.00

UCB Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


UCB Short-Term Debt Related Terms

Thank you for viewing the detailed overview of UCB's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


UCB Business Description

Address
Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

UCB Headlines

No Headlines